CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.License Agreement • September 17th, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations • Massachusetts
THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is entered into as of 25th February, 2021, effective as of the Effective Date. Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Agreement (as defined below).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution CopyLicense Agreement • September 17th, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations • Massachusetts
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENTLicense Agreement • September 17th, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 8th day of December, 2020 (the “Execution Date”), by and between Pyxis Oncology, Inc., a corporation organized and existing under the laws of Delaware with offices at 35 Cambridgepark Drive Suite 100-R, Cambridge, MA02140 (“Pyxis”) and Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”). Pyxis and Pfizer may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Amendment No. 1 to Agreement (“Amendment No. 1”)Agreement • September 17th, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations
WHEREAS, the parties hereto desire to amend, among other things, certain terms of the Agreement including the schedules of Licensed ADC Know-How and Licensed Platform Know-how
EXCLUSIVE LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF CHICAGO AND PYXIS ONCOLOGY FOR CANCER IMMUNOTHERAPY TECHNOLOGYExclusive License Agreement • September 17th, 2021 • Pyxis Oncology, Inc. • Pharmaceutical preparations • Illinois
This License Agreement (“Agreement”), dated April 16th, 2020 (the “Effective Date”), is between The University of Chicago, an Illinois not-for-profit corporation (“University”), and Pyxis Oncology, Inc., a Delaware corporation, having an address 800 Boylston St, Boston, MA 02199 (“Company”). Each hereunder may be referred to separately as the “Party”, or together as the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Pyxis Oncology, Inc. • September 17th, 2021 • Pharmaceutical preparations • Massachusetts
THIS OPT-IN, INVESTMENT AND ADDITIONAL CONSIDERATION AGREEMENT (the “Opt-In Agreement”) is made on December 1, 2020 (“Effective Date”) as part of the License between the Parties (each as defined below).
